BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharma is supported by Orladeyo’s durable performance in hereditary angioedema, with 3Q26 revenue of $175M helping total revenue reach $180M versus $166M expected and non-GAAP operating profit of $53M versus $41M. Management also raised FY26 total revenue guidance to $715M-$730M, kept Orladeyo guidance at $625M-$645M, and ended 3Q26 with $376M in cash and equivalents, reinforcing balance-sheet flexibility. The outlook is further strengthened by the pediatric pellet launch, 47 prescriptions already on a YTD basis, and upcoming pipeline catalysts including BCX17725 by YE26 and navenibart data in 3Q27, which could expand the company’s HAE franchise.

BioCryst Pharma is viewed negatively because its success hinges on regulatory outcomes that could demand additional data, longer studies, or narrower product labels that limit market traction. Commercially, the company must prove it can execute against entrenched HAE rivals such as Takhzyro and CSL Behring, while also defending against earlier-stage challengers like Pharvaris and Intellia Therapeutics. The risk profile is further elevated by financing concerns, as it may need additional external funding to advance its development platform and failure to access capital markets could delay or terminate development campaigns.